Skip to main content
TipRanks
Go Ultimate75% OFF

MEDICLIN (MED) AI Stock Analysis

1 Followers
DE:MED

MEDICLIN

(XETRA:MED)

Select Model
Rating:79Outperform
Price Target:EUR 6.00â–²(9.09% Upside)
Action:reiterated
Date:11/13/26

MEDICLIN achieves a strong overall score driven primarily by an appealing valuation (8.2x P/E) and a robust technical uptrend. The company's foundational turnaround—marked by significant debt reduction and net profitability growth—provides solid fundamental backing, although stabilizing recent gross margin pressures is crucial for sustained performance.

Positive Factors
DeleveragingThe substantial reduction in debt-to-equity indicates that MEDICLIN has strengthened its capital structure and reduced financial leverage. This should improve resilience, lower balance-sheet pressure, and provide greater flexibility to sustain operations or invest in its healthcare facilities over the coming quarters.
Negative Factors
Weak Revenue MomentumFlat TTM revenue and a sharply negative reported growth rate indicate weakening expansion across MEDICLIN’s hospital, rehabilitation, and nursing-care activities. Persistent top-line stagnation could limit operating leverage, constrain earnings growth, and make future improvement more dependent on cost control.

MEDICLIN (MED) vs. iShares MSCI Germany ETF (EWG)

-10%0%10%20%30%40%50%60%70%DE:MED+58.87%EWG+9.37%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 261.25M
Dividend Yield
0.73%
Average Volume (3M)
6,272
Price to Earnings (P/E)
8.4
Beta (1Y)
0.31
Revenue Growth
0.77%
EPS Growth
-11.41%
Country
Germany
Employees
7,048
Sector
General
Sector Strength
55
Industry
Medical - Care Facilities

MEDICLIN Business Overview & Revenue Model

Company Description

Mediclin AG is a German healthcare enterprise primarily engaged in managing hospitals across the nation. Its operations are categorized into three main segments: Post-Acute, Acute, and various other related activities. The company offers a comprehens...

How the Company Makes Money

MEDICLIN makes money primarily by operating healthcare facilities and charging for patient services delivered in its hospitals, rehabilitation clinics, and nursing care facilities. Key revenue streams typically include (1) payments for acute inpatien...

MEDICLIN Financial Statement Overview

Summary

MEDICLIN demonstrates a solid turnaround with highly effective deleveraging, consistent cash flow generation, and rebounding net profitability. However, a recent contraction in gross margins to negative territory remains a key operational risk.

Income Statement

65Positive

Balance Sheet

82Very Positive

Cash Flow

75Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Mar 2023Dec 2021
Income Statement
Total Revenue783.49M784.49M748.80M730.10M704.70M673.10M
Gross Profit-27.87M113.81M623.00M594.60M571.90M551.00M
EBITDA103.33M98.66M106.39M101.26M91.80M85.43M
Net Income31.06M25.49M24.84M-10.78M9.44M1.46M
Balance Sheet
Total Assets866.81M879.69M905.91M880.50M916.11M881.24M
Cash, Cash Equivalents and Short-Term Investments178.00M72.18M107.56M115.29M88.04M133.48M
Total Debt367.67M390.83M464.13M479.82M502.67M439.96M
Total Liabilities586.15M630.06M683.17M684.47M706.79M698.22M
Stockholders Equity279.75M248.95M222.51M195.92M209.21M183.28M
Cash Flow
Free Cash Flow48.60M51.44M35.88M40.43M8.62M64.96M
Operating Cash Flow91.91M99.87M80.57M78.00M34.64M81.97M
Investing Cash Flow-23.99M-37.14M-15.13M-9.51M-6.24M-7.09M
Financing Cash Flow-92.54M-97.40M-73.16M-45.48M-56.17M-55.26M

MEDICLIN Technical Analysis

Technical Analysis SentimentPositive
Last Price5.50

Price Trends

50DMA5.35Positive
100DMA4.94Positive
200DMA4.30Positive

Market Momentum

MACD0.05Negative
RSI55.95Neutral
STOCH56.67Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:MED, the sentiment is Positive. The current price of 5.50 is above the 20-day moving average (MA) of 5.35, above the 50-day MA of 5.35, and above the 200-day MA of 4.30, indicating a bullish trend. The MACD of 0.05 indicates Negative momentum. The RSI at 55.95 is Neutral, neither overbought nor oversold. The STOCH value of 56.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:MED.

MEDICLIN Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

DE:MED against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
DE:M12DE:M1279OutperformEUR 337.72M17.6116.58%6.25%-27.50%13.64%
DE:MEDDE:MED79OutperformEUR 261.25M8.3611.94%0.73%0.77%-11.41%
DE:LIKDE:LIK67NeutralEUR 175.50M31.6622.18%1.71%35.46%17.88%
DE:RHKDE:RHK61NeutralEUR 970.61M22.663.16%1.38%3.54%11.21%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
DE:MAKDE:MAK45NeutralEUR 17.09M-1.2516.80%―2.73%-1.80%

* General Sector Average

Performance Comparison

0%100%200%DE:MEDDE:RHKDE:MAKDE:LIKDE:JTH0DE:M12Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:MED and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:MEDMEDICLIN AG5.502.0257.96%
DE:RHKRHON-KLINIKUM AG14.502.5020.79%
DE:MAKMATERNUS-Kliniken AG0.81-0.28-25.23%
DE:LIKLimes Schlosskliniken AG585.00239.7069.42%
DE:JTH0Gesundheitswelt Chiemgau AG12.700.705.83%
DE:M12M1 Kliniken AG19.204.6732.16%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 13, 2026